TITLE

New technologies around biomarkers and their interplay with drug development

AUTHOR(S)
Dieterle, Frank; Marrer, Estelle
PUB. DATE
January 2008
SOURCE
Analytical & Bioanalytical Chemistry;Jan2008, Vol. 390 Issue 1, p141
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
What conductors are to their orchestras, biomarkers are to their associated technologies. Building fundamental science, supporting early diagnosis of diseases and following their progression, improving efficacy and safety of treatments, optimizing patient selection and adapting dosing of drugs, helping decide which therapy is most appropriate; these are examples of a few contexts in which biomarkers are key players. Technology development can definitely not escape being associated with these steps. In other words, today’s biomarkers are the thermometers of tomorrow’s therapies. This review provides an overview of recently established platforms as well as new and upcoming technologies for biomarker development in the context of drug development. The roles as well as the pros and cons of different disciplines such as genetics, genomics, proteomics, metabonomics, and assay development will be discussed.
ACCESSION #
28000650

 

Related Articles

  • Application of proteomics for discovery of protein biomarkers. Hale, John E.; Gelfanova, Valentina; Ludwig, James R.; Knierman, Michael D. // Briefings in Functional Genomics & Proteomics;Oct2003, Vol. 2 Issue 3, p185 

    Biomarkers of drug efficacy and toxicity are becoming a key need in the drug development process. Mass spectral-based proteomic technologies are ideally suited for the discovery of protein biomarkers in the absence of any prior knowledge of quantitative changes in protein levels. The success of...

  • Symposia.  // Annals of Clinical Biochemistry;Jan2006 Supplement, Vol. 43, p4 

    The clinical untility of pharmacogenetics: fact or fiction? M Lennard, Sheffield. 4 Natural toxins. F A de Wolff, Leiden, The Netherlands. 4 Post mortem toxicology. D Pounder, Dundee. 5 Tandem mass spectrometry. H Field, Leeds. 6 Recent progress in standardisation of immunoassays. C Sturgeon,...

  • The Role of Molecular Imaging in Drug Discovery and Development. Hargreaves, R. J. // Clinical Pharmacology & Therapeutics;Feb2008, Vol. 83 Issue 2, p349 

    Molecular imaging biomarkers are playing an increasingly important role in efforts to increase the probability of success of drug candidates by helping to validate novel drug targets in support of proof-of-concept testing early in the drug discovery and development process. By facilitating...

  • Industry perspectives on biomarker qualification. Lavezzari, G; Womack, AW // Clinical Pharmacology & Therapeutics;Feb2016, Vol. 99 Issue 2, p208 

    Biomarkers have the potential to expedite drug development, increase patient safety, and optimize clinical response. Yet few have achieved regulatory qualification. A survey was conducted to clarify industry's perspective on biomarker qualification and identify the most promising biomarkers for...

  • Immunoassays: Biological Tools for High Throughput Screening and Characterisation of Combinatorial Libraries. Taipa, M. Ângela // Combinatorial Chemistry & High Throughput Screening;May2008, Vol. 11 Issue 4, p325 

    In the demanding field of proteomics, there is an urgent need for affinity-catcher molecules to implement effective and high throughput methods for analysing the human proteome or parts of it. Antibodies have an essential role in this endeavour, and selection, isolation and characterisation of...

  • The importance of experimental design in proteomic mass spectrometry experiments: Some cautionary tales. Hu, Jianhua; Coombes, Kevin R.; Morris, Jeffrey S.; Baggerly, Keith A. // Briefings in Functional Genomics & Proteomics;Feb2005, Vol. 3 Issue 4, p322 

    Proteomic expression patterns derived from mass spectrometry have been put forward as potential biomarkers for the early diagnosis of cancer and other diseases. This approach has generated much excitement and has led to a large number of new experiments and vast amounts of new data. The data,...

  • Posters - Proteomics.  // Annals of Clinical Biochemistry;Jan2006 Supplement, Vol. 43, p111 

    Biomarkers and pathogenesis of HTLV-1-associated inflammatory disease. A P Courtney, London. 111

  • Development and standardization of multiplexed antibody microarrays for use in quantitative proteomics. Perlee, L. T.; Christiansen, J.; Dondero, R.; Grimwade, B.; Lejnine, S.; Mullenix, M.; Shao, W.; Sorette, M.; Tchernev, V. T.; Patel, D. D.; Kingsmore, S. F. // Proteome Science;2004, Vol. 2, p9 

    Background: Quantitative proteomics is an emerging field that encompasses multiplexed measurement of many known proteins in groups of experimental samples in order to identify differences between groups. Antibody arrays are a novel technology that is increasingly being used for quantitative...

  • Mass Spectrometric Immunoassay for the qualitative and quantitative analysis of the cytokine Macrophage Migration Inhibitory Factor (MIF). Sherma, Nisha D.; Borges, Chad R.; Trenchevska, Olgica; Jarvis, Jason W.; Rehder, Douglas S.; Oran, Paul E.; Nelson, Randall W.; Nedelkov, Dobrin // Proteome Science;2014, Vol. 12 Issue 1, p1 

    Background The cytokine MIF (Macrophage Migration Inhibitory Factor) has diverse physiological roles and is present at elevated concentrations in numerous disease states. However, its molecular heterogeneity has not been previously investigated in biological samples. Mass Spectrometric...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics